PND2 Efficacy and Safety of Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review

To conduct a systematic search to compare the efficacy and safety of disease-modifying therapies (DMTs) for treatment relapsing-remitting multiple sclerosis (RRMS). A literature PubMed was conducted identify phase III clinical trials in which DMTs RRMS were evaluated. The primary outcome this assessment annualized relapse rate (ARR). From with approximately 2-yr ARRs reported (n=13), outcomes as follows: Among 512 patients who received peginterferon beta-1a, ARR 0.22 vs. 0.35 delayed treatment, relative reduction 37%. 627 natalizumab, 0.23 0.73 placebo, 68%. 802 alemtuzumab, 0.18-0.26 0.39-0.52 interferon 49-55%. 827 ocrelizumab, 0.16 0.29 46-47%. 1,582 fingolimod, 0.16-0.21 0.40 48-60%. 366 teriflunomide, 0.37 0.54 31%. 1,530 dimethyl fumarate, 0.17-0.22 vs 0.36-0.40 44-53%. 889 cladribine, 0.14-0.15 0.33 54-58%. 872 ozanimod, 0.28 21%-38%. occurrence any serious adverse events ranged 7-20%. Of injectable, infused, oral evaluated review, all provided significant benefit reduction. Since comparators differed, further comparison studies are warranted.